earnings
Bayer Stock Rallies as Next-Gen Blood Thinner Achieves Phase 3 Success
Bayer; stock rally; blood thinner; Phase 3 trial; pharmaceuticals; earnings
Pfizer Cuts 11 R&D Programs amid Ongoing Revenue Declines and Cost Realignment Efforts
Pfizer; R&D cuts; revenue decline; cost savings; Q3 2025 earnings; COVID-19 product sales; digital enablement; AI in R&D; Seagen acquisition
BMS Battles Deeply Ingrained Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates
Bristol Myers Squibb; Cobenfy; schizophrenia; prescribing habits; dopamine D2 receptor; novel mechanism of action; quarterly earnings; drug market uptake; Alzheimer’s disease psychosis; atypical antipsychotics
Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook
Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation
GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report
GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress
Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data
Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations
Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street
Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth
AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology
AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals
Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward
Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin